The article reviews the complex relationship between bile acids and gastrointestinal carcinogenesis, focusing on colorectal cancer (CRC) and hepatocellular carcinoma (HCC). Bile acids, produced in the liver and metabolized by gut bacteria, play a crucial role in maintaining gut microbiota balance, lipid and carbohydrate metabolism, insulin sensitivity, and innate immunity. The authors highlight the importance of two major bile acid-sensing receptors, farnesoid X receptor (FXR) and G protein-coupled bile acid receptor (TGR5), in this process. They discuss how bile acids and the gut microbiota interact to influence gastrointestinal inflammation and carcinogenesis, emphasizing the role of these receptors in modulating cellular responses and immune functions. The review also explores strategies and cutting-edge technologies aimed at targeting the gut microbiota-dependent alterations in bile acid metabolism to combat gastrointestinal cancers. Key points include the impact of bile acid dysregulation on liver inflammation and HCC, as well as its role in colon inflammation and CRC. The authors suggest that restoring FXR signaling, re-establishing normal enterohepatic circulation of bile acids, and controlling gastrointestinal inflammation are crucial therapeutic approaches for treating gastrointestinal diseases.The article reviews the complex relationship between bile acids and gastrointestinal carcinogenesis, focusing on colorectal cancer (CRC) and hepatocellular carcinoma (HCC). Bile acids, produced in the liver and metabolized by gut bacteria, play a crucial role in maintaining gut microbiota balance, lipid and carbohydrate metabolism, insulin sensitivity, and innate immunity. The authors highlight the importance of two major bile acid-sensing receptors, farnesoid X receptor (FXR) and G protein-coupled bile acid receptor (TGR5), in this process. They discuss how bile acids and the gut microbiota interact to influence gastrointestinal inflammation and carcinogenesis, emphasizing the role of these receptors in modulating cellular responses and immune functions. The review also explores strategies and cutting-edge technologies aimed at targeting the gut microbiota-dependent alterations in bile acid metabolism to combat gastrointestinal cancers. Key points include the impact of bile acid dysregulation on liver inflammation and HCC, as well as its role in colon inflammation and CRC. The authors suggest that restoring FXR signaling, re-establishing normal enterohepatic circulation of bile acids, and controlling gastrointestinal inflammation are crucial therapeutic approaches for treating gastrointestinal diseases.